Xencor_XmAb819-01 (Clear Cell Renal Cell Carcinoma) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called XmAb819 (the study drug) is a safe and effective treatment for clear cell renal cell carcinoma (ccRCC).
What is the Condition Being Studied?
Clear Cell Renal Cell Carcinoma (ccRCC)
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with ccRCC
- Have not improved after receiving standard therapy
Para obtener más información sobre quién puede participar en este estudio, comuníquese con el equipo del estudio al 919-681-6468.
Grupo etario
Adultos
What is Involved?
Si elige unirse a este estudio, podrá:
- Get the study drug as either an intravenous infusion (IV) or as an injection under your skin
- Have a tumor biopsy
- Have physical exams, blood draws, and give urine samples
- Have imaging scans (CT and/or MRI)
- Have heart tests (ECG)
Study Details
Full Title
A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma
Principal Investigator
Christopher Hoimes
Protocol Number
IRB:
PRO00111480
NCT:
NCT05433142
Phase
Fase I
ClinicalTrials.gov
View on ClinicalTrials.gov
Estado de inscripción
Abierto para inscripción